Scarica l'app Stockscreener
4.57
2.70%
0.12
Dopo l'orario di chiusura:
4.57
Intensity Therapeutics Inc Borsa (INTS) Ultime notizie
Intensity Therapeutics Inc (INTS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Why Did INTS Stock Plummet 25% Today? - Stocktwits
Intensity Therapeutics Inc (INTS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
Intensity Therapeutics Inc (INTS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
INTS|Intensity Therapeutics Inc|Price:4.450|Chg%:+0.030 - TradingKey
INTS Stock Price, Quote & Chart - ChartMill
Intensity Therapeutics (INTS) Proxy filing Summary - Quartr
Intensity Therapeutics (INTS) Q1 2026 earnings summary - Quartr
Director Mark Goldberg awarded 5,500 options at Intensity Therapeutics (INTS) - Stock Titan
Intensity Therapeutics (INTS) awards director 5,500 options at $4.90 strike - Stock Titan
Intensity Therapeutics grants 5,500-share option to director | INTS Insider Trading - Stock Titan
Intensity Therapeutics (INTS) director awarded 5,500 stock options at $4.90 - Stock Titan
Intensity Therapeutics (INTS) grants 11,000 stock options to accounting officer - Stock Titan
Intensity Therapeutics (INTS) awards CFO 34,000 stock options at $4.90 - Stock Titan
Intensity Therapeutics grants 78,000 options to CEO | INTS Insider Trading - Stock Titan
Intensity Therapeutics Restarts Phase 2 TNBC Trial - t.co
Intensity Therapeutics (INTS) Edges Higher, Holding Above Key Support at $4.66Fear Greed Extreme - dars.gov.et
New patients dosed with INT230-6 in Swiss trial for aggressive triple-negative breast cancer - Pluang
Intensity Therapeutics (INTS) AGM 2026 Summary - Quartr
Intensity Therapeutics (INTS) Q4 2025 earnings summary - Quartr
Intensity Therapeutics restarts 61-patient breast cancer trial - grafa.com
Intensity Therapeutics resumes patient dosing in Swiss trial - Investing.com
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) - PR Newswire
Intensity Therapeutics (INTS) Surges 6.6%: Testing Key Resistance After Strong SessionInverse ETF Flow - dars.gov.et
INTS SEC FilingsINTENSITY THERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Intensity Therapeutics (INTS) Edges Lower, Testing Key Support at $3.91RSI Oversold Picks - dars.gov.et
Form 4 Intensity Therapeutics Inc For: 1 July By Investing.com - Investing.com Canada
ESPP purchase adds shares for Intensity Therapeutics (NASDAQ: INTS) officer - Stock Titan
Intensity Therapeutics (INTS) CFO adds 1,093 ESPP shares at discount - Stock Titan
Intensity Therapeutics updates INT230-6 cancer trials - grafa.com
Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 - PR Newswire
Price to sales forward of Intensity Therapeutics, Inc. – NASDAQ:INTS - TradingView
Price to book forward of Intensity Therapeutics, Inc. – NASDAQ:INTS - TradingView
Price to earnings forward of Intensity Therapeutics, Inc. – NASDAQ:INTS - TradingView
Enterprise value to EBITDA forward of Intensity Therapeutics, Inc. – NASDAQ:INTS - TradingView
Intensity Therapeutics, Inc. Actuals & Estimates (NASDAQ:INTS) - TradingView
Enterprise value to revenue forward of Intensity Therapeutics, Inc. – NASDAQ:INTS - TradingView
INTS Forecast — Price Target — Prediction for 2027 - TradingView
Intensity Therapeutics Inc (INTS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Intensity Therapeutics Inc (INTS) Institutional Confidence - TradingKey
Intensity Therapeutics Inc (INTS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Intensity Therapeutics Inc (INTS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Intensity Therapeutics Stockholders Approve Proposals at Annual Meeting - The Globe and Mail
Intensity Therapeutics Inc (INTS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Intensity Therapeutics Inc (INTS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Intensity Therapeutics shareholders approve board proposals at annual meeting By Investing.com - Investing.com Nigeria
Intensity Therapeutics shareholders approve board proposals at annual meeting - Investing.com
Intensity Therapeutics (NASDAQ: INTS) OKs share plan increases and board elections - Stock Titan
INTS: All proposals, including director elections and stock plan amendments, were approved by majority vote - TradingView
INTS Q1 2026 Earnings: Narrower-than-Expected Loss Surprises as Clinical Progress ContinuesROE Trend Analysis - dars.gov.et
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):